Clinical Pharmacology
Conditions
Brief summary
Researchers in this study wanted to compare the effect of the formulation (orally disintegrating tablet and film-coated tablet) on the bioequivalence of drug Rivaroxaban (brand name: Xarelto) at dose of 10 mg in Japanese healthy male subjects aged 20 to 40 years. Rivaroxaban is an approved drug to be used for the prevention of events/diseases caused by blood clots. Currently, there are two formulations of Rivaroxaban available on the market in Japan and they are film-coated tablets and fine granules. To further improve patients' convenience, a new formulation, orally disintegrating tablet (ODT, a drug dosage form designed to be dissolved on the tongue rather than swallowed whole) is under development. The goal of this study was to compare the effect of this new formulation with film-coated tablets when taken with or without water. Participants in this study received one oral dose of rivaroxaban 10 mg ODT either with or without water and one oral dose of rivaroxaban 10 mg film-tablet. There were at least 5 days between the two doses. Observation for each participant lasted about 6 weeks in total. Blood samples were collected from the participants to measure the blood level of the study drug.
Interventions
10 mg as 1 x 10 mg orally disintegrating tablet (ODT)
10 mg as 1 x 10 mg film-coated tablet
Sponsors
Janssen Research & Development, LLC
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
20 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
\- Japanese healthy male subjects, aged 20 to 40 years (inclusive), with body mass index 17.6 to 26.4 kg/m²
Exclusion criteria
* Subject with incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study drugs will not be normal * Subject with known hypersensitivity to the study drugs (active substances or excipients of the preparations) * Subject with known coagulation disorders (e.g. von Willebrand disease, hemophilia) * Subject with febrile illness within 1 week before the first study drug administration * Subject with suspicion of drug or alcohol abuse * Subject with intake of foods or beverages containing grapefruit, pomelo, Seville orange, and tangelo within 1 week before the first study drug administration * Subject with therapies (e.g. physiotherapy, acupuncture, etc.) within 1 month before starting study treatment * Subject with clinically relevant findings in the electrocardiogram (ECG) such as a second- or third-degree atrioventricular block, prolongation of the QRS complex over 120 msec or of the corrected QT (QTc) interval over 450 msec * Subject with systolic blood pressure below 90 or above 130 mmHg * Subject with diastolic blood pressure below 45 or above 85 mmHg * Subject with clinically relevant deviations of the screened laboratory parameters from reference ranges
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax for plasma rivaroxaban concentration | Up to 48 hours after study medication | Maximum observed concentration |
| AUC(0-tlast) for plasma rivaroxaban concentration | Up to 48 hours after study medication | Area under the concentration versus time curve from time 0 to the last data point \> lower limit of quantitation |
Secondary
| Measure | Time frame |
|---|---|
| Number of subjects with treatment-emergent adverse events | Up to 30 days after study medication |
Countries
Japan
Outcome results
None listed